Novel selective β(1)-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease

β-Blockers reduce mortality and improve symptoms in people with heart disease; however, current clinically available β-blockers have poor selectivity for the cardiac β(1)-adrenoceptor (AR) over the lung β(2)-AR. Unwanted β(2)-blockade risks causing life-threatening bronchospasm and reduced efficacy...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:FASEB J
Asıl Yazarlar: Baker, Jillian G., Gardiner, Sheila M., Woolard, Jeanette, Fromont, Christophe, Jadhav, Gopal P., Mistry, Shailesh N., Thompson, Kevin S. J., Kellam, Barrie, Hill, Stephen J., Fischer, Peter M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Federation of American Societies for Experimental Biology 2017
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5471521/
https://ncbi.nlm.nih.gov/pubmed/28400472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fj.201601305R
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller